Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23556199 | 0.82 | CA14 (0.37) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL25794000 | 0.79 | CA12 (0.38) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL24685880 | 0.79 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL3940725 | 0.79 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL17993754 | 0.78 | CA14 (0.40) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL14300394 | 0.77 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL1962792 | 0.76 | MEN1 (0.45) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL12160052 | 0.76 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14CA12 | |
| SCHEMBL25036963 | 0.75 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL18329838 | 0.75 | MAPK1 (0.34) | HDAC6HDAC1HDAC2CA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | HDAC6 75/4885HDAC1 230/4885HDAC2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.